PA
PETS icon

PharVision Advisers’s PetMed Express PETS Stock Holding History

PharVision Advisers’s Portfolio PETS Stock Details PETS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-36,859
Closed -$178K – 460
2024
Q4 		$178K Buy
+36,859
New +$173K 0.15% 331

Other funds holding PETS

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
OCMI
Oaktop Capital Management II Chatham, New Jersey $1.34B AUM 114.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PharVision Advisers's PETS Position: Q1 2025 in Review

PharVision Advisers sold out of PetMed Express (PETS) in Q1 2025, closing a stake of 36,859 shares — an estimated $178K sold.

PharVision Advisers first reported a position in PETS in Q4 2024 and held it in 1 quarter. The position peaked at $178K in Q4 2024. 72 funds tracked by Wall St. Rank hold PETS as of Q1 2025.

  • PharVision Advisers reported no remaining PetMed Express position as of Q1 2025 after selling out during the quarter.
  • PharVision Advisers sold 36,859 PetMed Express shares in Q1 2025, an estimated $178K.
  • PharVision Advisers first reported a position in PetMed Express in Q4 2024 and held it in 1 quarter.
  • PharVision Advisers's PetMed Express position peaked at $178K in Q4 2024.
  • 72 funds tracked by Wall St. Rank held PetMed Express as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.